Actively Recruiting
Neoadjuvant Chemotherapy with PD-L1VEGF Bispecific Antibody Versus PD-1 Monoclonal Antibody in Locally Advanced Non-Small Cell Lung Cancer A Randomized Controlled Trial
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-10-07
290
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating neoadjuvant chemotherapy combined with either a PD-L1VEGF bispecific antibody or a PD-1 monoclonal antibody in patients with locally advanced stage II-III non-small cell lung cancer NSCLC. This phase 3 randomized controlled trial aims to improve pathological response rates, event-free survival, and overall prognosis by targeting both immune suppression and tumor blood vessel formation simultaneously. The study addresses the potential benefits of combining these antibodies with chemotherapy before surgery. Participants are randomly assigned to one of two groups one receives four cycles of neoadjuvant treatment with a PD-L1VEGF bispecific antibody plus platinum-based doublet chemotherapy, and the other receives four cycles of neoadjuvant treatment with a PD-1 monoclonal antibody plus platinum-based doublet chemotherapy. After neoadjuvant therapy, those with tumors that can be surgically removed will undergo surgery. The bispecific antibody targets both PD-L1 and VEGF, while the monoclonal antibody targets PD-1, and both are given at specified doses on scheduled days. Throughout the study, participants will be closely monitored with assessments including pathological complete response rate up to 30 months, event-free survival, overall survival up to 60 months, and evaluations of treatment-related adverse events and quality of life. The study includes imaging exams, performance status evaluation, and organ function tests to ensure safety and suitability for surgery. Follow-up will continue to assess long-term outcomes and the effects of the treatments over time.
CONDITIONS
Brief Title
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
Research Team
P
Peng Zhang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here